Michael G Schlossmacher

List of Publications by Year
in descending order

82 papers	13,289 citations	38742 50 h-index	64796 79 g-index
91 all docs	91 docs citations	91 times ranked	12417 citing authors

#	Article	IF	Citations
1	Amyloid Î²-peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359, 322-325.	27.8	1,919
2	Phosphorylation of Ser-129 Is the Dominant Pathological Modification of Î±-Synuclein in Familial and Sporadic Lewy Body Disease. Journal of Biological Chemistry, 2006, 281, 29739-29752.	3.4	1,113
3	Ubiquitination of a New Form of Î±-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease. Science, 2001, 293, 263-269.	12.6	1,033
4	Dopamine covalently modifies and functionally inactivates parkin. Nature Medicine, 2005, 11, 1214-1221.	30.7	658
5	Detection of oligomeric forms of Î±â€synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB Journal, 2006, 20, 419-425.	0.5	646
6	Î±-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurology, The, 2011, 10, 230-240.	10.2	573
7	Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 955-960.	7.1	462
8	Decreased Î±-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinsonâ€™s disease. Biochemical and Biophysical Research Communications, 2006, 349, 162-166.	2.1	386
9	Direct quantification of CSF Î±-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology, 2008, 213, 315-325.	4.1	334
10	Parkin Localizes to the Lewy Bodies of Parkinson Disease and Dementia with Lewy Bodies. American Journal of Pathology, 2002, 160, 1655-1667.	3.8	299
11	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurology, The, 2007, 6, 652-662.	10.2	290
12	CNS expression of glucocerebrosidase corrects Î±-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12101-12106.	7.1	282
13	Multiple system atrophy: A primary oligodendrogliopathy. Annals of Neurology, 2008, 64, 239-246.	5.3	279
14	Acid Î²â€glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter Î±â€synuclein processing. Annals of Neurology, 2011, 69, 940-953.	5.3	276
15	Aggregated Â-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo. Journal of Neuroscience, 2007, 27, 3338-3346.	3.6	271
16	Lewy body Parkinson's disease in a large pedigree with 77Parkin mutation carriers. Annals of Neurology, 2005, 58, 411-422.	5.3	252
17	GATA transcription factors directly regulate the Parkinson's disease-linked gene Î±-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10907-10912.	7.1	251
18	Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Molecular Brain, 2009, 2, 5.	2.6	232

#	Article	IF	Citations
19	Parkinsonâ€™s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. Journal of Neural Transmission, 2011, 118, 795-808.	2.8	230
20	Structure of acid Î²-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature Chemical Biology, 2007, 3, 101-107.	8.0	213
21	Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder. Neurology, 2007, 69, 2093-2104.	1.1	191
22	The genetics of Parkinson disease: implications for neurological care. Nature Clinical Practice Neurology, 2006, 2, 136-146.	2.5	153
23	Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology, 2013, 81, 1226-1234.	1.1	153
24	RING finger 1 mutations in Parkin produce altered localization of the protein. Human Molecular Genetics, 2003, 12, 2957-2965.	2.9	138
25	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
26	Total CSF Î±-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neuroscience Letters, 2013, 532, 44-48.	2.1	130
27	Unrecognized vitamin D ₃ deficiency is common in Parkinson disease. Neurology, 2013, 81, 1531-1537.	1.1	119
28	Quantification of Î±-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomarkers in Medicine, 2010, 4, 683-699.	1.4	113
29	Normal Cellular Processing of the Î²â€Amyloid Precursor Protein Results in the Secretion of the Amyloid Î² Peptide and Related Molecules^a. Annals of the New York Academy of Sciences, 1993, 695, 109-116.	3.8	112
30	Alphaâ€synuclein in the appendiceal mucosa of neurologically intact subjects. Movement Disorders, 2014, 29, 991-998.	3.9	107
31	Expansion of the Parkinson disease-associated SNCA- Rep1 allele upregulates human Î±-synuclein in transgenic mouse brain. Human Molecular Genetics, 2009, 18, 3274-3285.	2.9	101
32	Canadian guideline for Parkinson disease. Cmaj, 2019, 191, E989-E1004.	2.0	90
33	Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinsonâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5164-E5173.	7.1	83
34	Parkin Protects against Mitochondrial Toxins and Î²-Amyloid Accumulation in Skeletal Muscle Cells. Journal of Biological Chemistry, 2006, 281, 12809-12816.	3.4	81
35	The effects of oxidative stress on parkin and other E3 ligases. Journal of Neurochemistry, 2007, 103, 2354-2368.	3.9	78
36	Alpha-synuclein research: defining strategic moves in the battle against Parkinsonâ€™s disease. Npj Parkinson's Disease, 2021, 7, 65.	5.3	74

#	Article	IF	Citations
37	Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 15918-15923.	7.1	72
38	Detection of soluble forms of the Î²-amyloid precursor protein in human plasma. Biochemical and Biophysical Research Communications, 1990, 167, 1094-1101.	2.1	71
39	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiology of Disease, 2015, 80, 29-41.	4.4	71
40	Association between Î±-synuclein blood transcripts and early, neuroimaging-supported Parkinsonâ€™s disease. Brain, 2015, 138, 2659-2671.	7.6	69
41	Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner. Science Translational Medicine, 2019, 11, .	12.4	67
42	Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies. Neurodegenerative Diseases, 2007, 4, 366-375.	1.4	65
43	Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinsonâ€™s disease. Journal of Neuroinflammation, 2017, 14, 164.	7.2	64
44	Î±-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. Journal of Neural Transmission, 2012, 119, 739-746.	2.8	63
45	Parkin-Dependent Degradation of the F-Box Protein Fbw7Î² Promotes Neuronal Survival in Response to Oxidative Stress by Stabilizing Mcl-1. Molecular and Cellular Biology, 2013, 33, 3627-3643.	2.3	62
46	Detection of distinct isoform patterns of the Î²-amyloid precursor protein in human platelets and lymphocytes. Neurobiology of Aging, 1992, 13, 421-434.	3.1	61
47	Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains. Molecular Neurodegeneration, 2009, 4, 12.	10.8	59
48	Dimerization of Parkinson's disease-causing DJ-1 and formation of high molecular weight complexes in human brain. Molecular and Cellular Neurosciences, 2004, 27, 236-246.	2.2	58
49	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. Journal of Neurochemistry, 2016, 139, 290-317.	3.9	58
50	Novel One-step Immunoassays to Quantify Î±-Synuclein. Journal of Biological Chemistry, 2012, 287, 33691-33705.	3.4	51
51	AÎ² oligomers induce pathophysiological mGluR5 signaling in Alzheimerâ€™s disease model mice in a sex-selective manner. Science Signaling, 2020, 13, .	3.6	45
52	Holocranohistochemistry enables the visualization of Î±-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. Journal of Neural Transmission, 2017, 124, 721-738.	2.8	42
53	Synphilin-1 and parkin show overlapping expression patterns in human brain and form aggresomes in response to proteasomal inhibition. Neurobiology of Disease, 2005, 20, 401-411.	4.4	40
54	Towards translational therapies for multiple system atrophy. Progress in Neurobiology, 2014, 118, 19-35.	5.7	35

#	Article	IF	Citations
55	Age-associated insolubility of parkin in human midbrain is linked to redox balance and sequestration of reactive dopamine metabolites. Acta Neuropathologica, 2021, 141, 725-754.	7.7	32
56	Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of Î±-synuclein and other proteins in cerebrospinal fluid. Methods, 2012, 56, 514-518.	3.8	30
57	Mutant <i>GBA1</i> Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models. Neurodegenerative Diseases, 2012, 10, 195-202.	1.4	26
58	LRRK2 and Nod2 promote lysozyme sorting in Paneth cells. Nature Immunology, 2015, 16, 898-900.	14.5	26
59	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology, 2018, 90, 74-82.	1.1	23
60	Association of SNCA with Parkinson: Replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders, 2011, 26, 2283-2286.	3.9	21
61	Considerations Regarding the Etiology and Future Treatment of Autosomal Recessive Versus Idiopathic Parkinson Disease. Current Treatment Options in Neurology, 2012, 14, 230-240.	1.8	21
62	Biomarker research in Parkinsonâ€™s disease: objective measures needed for patient stratification in future cause-directed trials. Biomarkers in Medicine, 2010, 4, 647-650.	1.4	18
63	Respiratory infection of mice with mammalian reoviruses causes systemic infection with age and strain dependent pneumonia and encephalitis. Virology Journal, 2013, 10, 67.	3.4	17
64	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: theÂP_REDIGT score. European Journal of Neuroscience, 2017, 45, 175-191.	2.6	17
65	Neurodegeneration: Impact of S-nitrosylated Parkin, DJ-1 and PINK1 on the pathogenesis of Parkinson's disease. Archives of Biochemistry and Biophysics, 2021, 704, 108869.	3.0	16
66	Parkinson's Disease: Assays for the Ubiquitin Ligase Activity of Neural Parkin. , 2005, 301, 351-370.		15
67	DMS as an orthogonal separation to LC/ESI/MS/MS for quantifying isomeric cerebrosides in plasma and cerebrospinal fluid. Journal of Lipid Research, 2019, 60, 200-211.	4.2	15
68	Case 27-2004. New England Journal of Medicine, 2004, 351, 912-922.	27.0	13
69	The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. New England Journal of Medicine, 2005, 352, 728-31; author reply 728-31.	27.0	13
70	Translational Research in Neurology and Neuroscience 2011. Archives of Neurology, 2011, 68, 709-16.	4.5	12
71	Protective effect of vagotomy suggests source organ for <scp>P</scp>arkinson disease. Annals of Neurology, 2015, 78, 834-835.	5.3	12
72	Microglia depletion prior to lipopolysaccharide and paraquat treatment differentially modulates behavioral and neuronal outcomes in wild type and G2019S LRRK2 knock-in mice. Brain, Behavior, & Immunity - Health, 2020, 5, 100079.	2.5	9

#	Article	IF	Citations
73	CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 590-591.	1.9	7
74	Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome. Microbes and Infection, 2020, 22, 40-45.	1.9	7
75	A First Tetraplex Assay for the Simultaneous Quantification of Total Î±-Synuclein, Tau, Î²-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid. PLoS ONE, 2016, 11, e0153564.	2.5	6
76	Chapter 8 Î±-Synuclein and Synucleinopathies. Blue Books of Neurology, 2007, 30, 186-215.	0.1	4
77	CSF Î±-synuclein, tau, and amyloid Î² in Parkinson's disease â€“ Authors' reply. Lancet Neurology, The, 2011, 10, 681-683.	10.2	4
78	BATL: Bayesian annotations for targeted lipidomics. Bioinformatics, 2022, 38, 1593-1599.	4.1	3
79	Performance report for a 10-year-old MD/PhD Program: A survey of trainees at the University of Ottawa. Clinical and Investigative Medicine, 2020, 43, E1-13.	0.6	2
80	Colocalization of Parkin with Î±-Synuclein in the Lewy Bodies of Parkinson Disease. Advances in Behavioral Biology, 2002, , 297-300.	0.2	1
81	Purification and Quantification of Neural Î±-synuclein. , 2008, , 559-573.		1
82	Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?. Movement Disorders, 2020, 35, 1922-1932.	3.9	0